Gonadotropin-releasing hormone agonist to induce final oocyte maturation prevents the development of ovarian hyperstimulation syndrome in high-risk patients and leads to improved clinical outcomes compared with coasting

Agonist and antagonist coast

No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles

Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin-releasing hormone agonist–triggered assisted reproductive technique cycles: understanding a new approach

Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study

Agonist trigger: what is the best approach? Agonist trigger with vitrification of oocytes or embryos

Ovarian hyperstimulation syndrome

Preventing ovarian hyperstimulation with gonadotropin-releasing hormone agonist trigger: is anything perfect?

Fewer medications for in vitro fertilization can be better: thinking outside the box

Luteal phase support for frozen embryo transfer cycles: intramuscular or vaginal progesterone?

Novel follicular-phase gonadotropin-releasing hormone antagonist stimulation protocol for in vitro fertilization in the poor responder

Pretreatment with oral contraceptives in infertile anovulatory patients with polycystic ovary syndrome who receive gonadotropins for controlled ovarian stimulation

Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists

Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins, and early pregnancy loss

The updated Cochrane review 2014 on GnRH agonist trigger: an indispensable piece of information for the clinician

Combination of gonadotropin-releasing hormone (GnRH) agonists with GnRH antagonists before chemotherapy reduce but does not completely prevent a follicle-stimulating hormone flare-up